Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
New subclade K flu strain raises concerns: What families should know - 2Portable Installment Answers for Independent ventures
- 3Experience Unrivaled Sound: Top Speakers You Really want to Hear
- 4Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- 5Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- Iranian rockets hit Tel Aviv area, injuring six
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- Treasure trove found in Egyptian tomb solves ancient mystery
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Iran plans new restrictions in overhaul of Strait of Hormuz rules
- Disability rights activist and author Alice Wong dies at 51
- Before Cheap Cars Were Common, This Fiat Changed Everyday Life for Millions
- Survey: Protected And Versatile Men's Razor
